NO20050526L - Bruk av PPAR-ALFA agonist for behandling av vektokning forbundet med PPAR-GAMMA-agonistbehandling - Google Patents

Bruk av PPAR-ALFA agonist for behandling av vektokning forbundet med PPAR-GAMMA-agonistbehandling

Info

Publication number
NO20050526L
NO20050526L NO20050526A NO20050526A NO20050526L NO 20050526 L NO20050526 L NO 20050526L NO 20050526 A NO20050526 A NO 20050526A NO 20050526 A NO20050526 A NO 20050526A NO 20050526 L NO20050526 L NO 20050526L
Authority
NO
Norway
Prior art keywords
ppar
agonist
treatment
weight gain
alfa
Prior art date
Application number
NO20050526A
Other languages
English (en)
Norwegian (no)
Inventor
Jean-Louis Junien
Alan Dunlap Edgar
Evelyne Chaput
Original Assignee
Fournier Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02291994A external-priority patent/EP1388351A1/en
Application filed by Fournier Lab Sa filed Critical Fournier Lab Sa
Publication of NO20050526L publication Critical patent/NO20050526L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20050526A 2002-08-08 2005-01-31 Bruk av PPAR-ALFA agonist for behandling av vektokning forbundet med PPAR-GAMMA-agonistbehandling NO20050526L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02291994A EP1388351A1 (en) 2002-08-08 2002-08-08 Use of fibrate to treat weight gain associated with rosiglitazone treatment
EP02292830A EP1388352A1 (en) 2002-08-08 2002-11-14 Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment
PCT/EP2003/008756 WO2004018041A1 (en) 2002-08-08 2003-08-06 Use of a ppar-alpha agonist to treat weight gain associated with a ppar-gamma agonist treatment

Publications (1)

Publication Number Publication Date
NO20050526L true NO20050526L (no) 2005-03-02

Family

ID=30445152

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050526A NO20050526L (no) 2002-08-08 2005-01-31 Bruk av PPAR-ALFA agonist for behandling av vektokning forbundet med PPAR-GAMMA-agonistbehandling

Country Status (10)

Country Link
US (2) US20040110799A1 (es)
EP (2) EP1388352A1 (es)
JP (1) JP4588448B2 (es)
CN (1) CN1674959A (es)
AT (1) ATE536913T1 (es)
AU (1) AU2003260380B2 (es)
CA (1) CA2493747A1 (es)
ES (1) ES2379165T3 (es)
NO (1) NO20050526L (es)
WO (1) WO2004018041A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600046A (es) 2005-02-09 2006-09-25 Terapia de combinacion

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
EP0842925A1 (en) 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
US4981784A (en) 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
CA2067216A1 (en) 1989-10-25 1991-04-26 Cary Alan Weinberger Receptor infection assay
CA2034220A1 (en) 1990-01-16 1991-07-17 Donald P. Mcdonnell Expression vectors that produce steroid receptors, steroid receptor chimera, screening assays for steroid receptors and clinical assays using synthesized receptors and receptor vector
DE69116563T3 (de) 1990-09-21 2006-07-06 The Salk Institute For Biological Studies, La Jolla Durch protoonkogenischen Proteinkomplex AP-1 kontrollierte Verfahren
GB9027023D0 (en) 1990-12-12 1991-01-30 Wellcome Found Anti-atherosclerotic aryl compounds
JPH07503609A (ja) 1991-12-06 1995-04-20 ザ　ソールク　インスチチュート　フォア　バイオロジカル　スタディズ リセプターのステロイド／甲状腺スーパーファミリーのメンバーの多量体型
JPH07509694A (ja) 1992-05-14 1995-10-26 ベイラー・カレッジ・オブ・メディシン 突然変異したステロイドホルモン受容体，その使用方法および遺伝子治療のための分子スイッチ
JPH08512197A (ja) 1993-04-07 1996-12-24 リガンド・ファーマシューティカルズ・インコーポレーテッド 受容体アゴニストのスクリーニング方法
US5506102A (en) 1993-10-28 1996-04-09 Ligand Pharmaceuticals Incorporated Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription
JPH09504111A (ja) 1993-12-30 1997-04-22 ザ ソールク インスチチュート フォア バイオロジカル スタディズ Ｇａｌ４−受容体構築体の新規な使用
AU719146B2 (en) 1996-02-02 2000-05-04 Merck & Co., Inc. Antidiabetic agents
AU712607B2 (en) 1996-02-02 1999-11-11 Merck & Co., Inc. Method of treating diabetes and related disease states
AU708055B2 (en) 1996-02-02 1999-07-29 Merck & Co., Inc. Heterocyclic derivatives as antidiabetic and antiobesity agents
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
JP2002503202A (ja) 1996-02-02 2002-01-29 メルク エンド カンパニー インコーポレーテッド 抗糖尿病薬
EP0930882A2 (en) * 1996-08-02 1999-07-28 Institut Pasteur De Lille Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
TW438784B (en) 1997-08-29 2001-06-07 Ssp Co Ltd Triazole derivative or salt thereof and pharmaceutical composition for treating mycosis containing the same
AU4713499A (en) * 1998-06-27 2000-01-17 Photogenesis, Inc. Ophthalmic uses of ppargamma agonists and ppargamma antagonists
CA2329004C (en) * 1998-06-30 2009-04-14 Takeda Chemical Industries, Ltd. Combination of insulin sensitizer with anorectic for treating or preventing diabetes
JP2003531171A (ja) 2000-04-19 2003-10-21 トーマス ジュリアス ボロディー 高脂血症関連疾患に対する組成物および治療
DE60128475T2 (de) * 2000-07-25 2008-02-07 Merck & Co., Inc. N-substituierte indole mit anwendung in der behandlung von diabetes
TWI354568B (en) * 2000-09-20 2011-12-21 Jagotec Ag Insoluble drug particle compositions with improved
AU2001291233A1 (en) * 2000-10-05 2002-04-15 Dr. Reddy's Research Foundation Polymorphs of pioglitazone hydrochloride and their use as antidiabetics
WO2002080936A1 (en) * 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators

Also Published As

Publication number Publication date
US20090099238A1 (en) 2009-04-16
EP1388352A1 (en) 2004-02-11
EP1526894A1 (en) 2005-05-04
CN1674959A (zh) 2005-09-28
JP4588448B2 (ja) 2010-12-01
US20040110799A1 (en) 2004-06-10
WO2004018041A1 (en) 2004-03-04
ATE536913T1 (de) 2011-12-15
CA2493747A1 (en) 2004-03-04
AU2003260380A1 (en) 2004-03-11
JP2005539033A (ja) 2005-12-22
ES2379165T3 (es) 2012-04-23
EP1526894B1 (en) 2011-12-14
AU2003260380B2 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
NO20051521L (no) Anvendelse av kombinasjonen av ciclesonid og antihistaminer for behandlingen av allergisk rhinitt
NO20051692L (no) Anvendelse av indolylderivater for fremstilling av et medikament for behandling av allergisk rhinitt
ATE408601T1 (de) Fredericamycin-derivate
PL374865A1 (en) Treatment of tnf alpha related disorders
GB0318447D0 (en) Therapeutic agents
GB0223038D0 (en) Therapeutic compounds
EP1490044A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMABLE COMPONENTS
ATE356621T1 (de) (s)-2-n-propylamino-5-hydroxytetralin als d3- agonistisches therapeutikum
HK1080467A1 (en) Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders
NO20055098D0 (no) Anvendelse av 10-hydroksy-10,11-dihydrokarbamazepinderivater for behandling av affektive forstyrrelser
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
HRP20050579B1 (hr) Nove sinergistiäśne kombinacije koje sadrže roflumilast i formoterol
DK1610864T3 (da) Elektromagnetisk stimulering af patienter med osteoporose
NO20054700L (no) Anvendelse av et fibrat og orlistat for behandling av fedme
ATE289196T1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
NO20050526L (no) Bruk av PPAR-ALFA agonist for behandling av vektokning forbundet med PPAR-GAMMA-agonistbehandling
NO20045343L (no) Ny kombinasjon for behandling av luftveisforstyrrelser
EA200600989A1 (ru) Применение габоксадола для лечения бессонницы
TW200512183A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of frailty, muscle damage or sarcopenia
NO20045344L (no) Kombinasjon for behandling av luftveisforstyrrelser
RS52038B (en) USE OF 7-BUTOXYIMINOMETHYLAMPTOTECIN FOR THE TREATMENT OF NON-PLASMA NEOPLASMS
NO20051468L (no) Behandling av ikke-allergisk rhinitt med selektive fosfodiesterase-4-inhibitorer
NO20053612L (no) 1,2,4-triaminobenzenderivater nyttige for behandling av forstyrrelser i sentralnervesystemet
HUP0101350A2 (hu) Generalizált szorongásos rendellenesség kezelése paroxetinnel
ITMI20022594A1 (it) Combinazione terapeutica per la cura dell'ipertensione.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application